These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32781957)

  • 1. Recent Advances in the Development of Fatty Acid Synthase Inhibitors as Anticancer Agents.
    Singh S; Karthikeyan C; Moorthy NSHN
    Mini Rev Med Chem; 2020; 20(18):1820-1837. PubMed ID: 32781957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?
    Lupu R; Menendez JA
    Curr Pharm Biotechnol; 2006 Dec; 7(6):483-93. PubMed ID: 17168665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatty acid synthase inhibitors: new directions for oncology.
    Kridel SJ; Lowther WT; Pemble CW
    Expert Opin Investig Drugs; 2007 Nov; 16(11):1817-29. PubMed ID: 17970640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (-)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer.
    Crous-Masó J; Palomeras S; Relat J; Camó C; Martínez-Garza Ú; Planas M; Feliu L; Puig T
    Molecules; 2018 May; 23(5):. PubMed ID: 29751678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Pathways: Fatty Acid Synthase.
    Jones SF; Infante JR
    Clin Cancer Res; 2015 Dec; 21(24):5434-8. PubMed ID: 26519059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatty Acid Synthase: An Emerging Target in Cancer.
    Fhu CW; Ali A
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32872164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diacylglycerol Metabolism and Signaling Is a Driving Force Underlying FASN Inhibitor Sensitivity in Cancer Cells.
    Benjamin DI; Li DS; Lowe W; Heuer T; Kemble G; Nomura DK
    ACS Chem Biol; 2015 Jul; 10(7):1616-23. PubMed ID: 25871544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review on target domains and natural compound-based inhibitors of fatty acid synthase for anticancer drug discovery.
    Pulla LSS; Begum Ahil S
    Chem Biol Drug Des; 2021 Nov; 98(5):869-884. PubMed ID: 34459114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel small-molecule fatty acid synthase inhibitor with antitumor activity by cell cycle arrest and cell division inhibition.
    Qu H; Shan K; Tang C; Cui G; Fu G; Qi Y; Cui J; Li J; Wang R; Feng N; Chen YQ
    Eur J Med Chem; 2021 Jul; 219():113407. PubMed ID: 33901805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatty acid synthase as a potential therapeutic target in cancer.
    Flavin R; Peluso S; Nguyen PL; Loda M
    Future Oncol; 2010 Apr; 6(4):551-62. PubMed ID: 20373869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in the development of fatty acid synthase inhibitors as anticancer targets.
    Mullen GE; Yet L
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4363-9. PubMed ID: 26364942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors.
    Angeles TS; Hudkins RL
    Expert Opin Drug Discov; 2016 Dec; 11(12):1187-1199. PubMed ID: 27701891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?
    Lupu R; Menendez JA
    Endocrinology; 2006 Sep; 147(9):4056-66. PubMed ID: 16809439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effect of emodin on fatty acid synthase, colon cancer proliferation and apoptosis.
    Lee KH; Lee MS; Cha EY; Sul JY; Lee JS; Kim JS; Park JB; Kim JY
    Mol Med Rep; 2017 Apr; 15(4):2163-2173. PubMed ID: 28260110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Inhibitor of Fatty Acid Synthase Thioesterase Domain with Improved Cytotoxicity against Breast Cancer Cells and Stability in Plasma.
    Lupien LE; Dunkley EM; Maloy MJ; Lehner IB; Foisey MG; Ouellette ME; Lewis LD; Pooler DB; Kinlaw WB; Baures PW
    J Pharmacol Exp Ther; 2019 Oct; 371(1):171-185. PubMed ID: 31300609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells.
    Wagner R; Stübiger G; Veigel D; Wuczkowski M; Lanzerstorfer P; Weghuber J; Karteris E; Nowikovsky K; Wilfinger-Lutz N; Singer CF; Colomer R; Benhamú B; López-Rodríguez ML; Valent P; Grunt TW
    Oncotarget; 2017 Feb; 8(7):11600-11613. PubMed ID: 28086243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyridine derivatives as anticancer lead compounds with Fatty Acid Synthase as the target: An in silico-guided in vitro study.
    Amrutha NA; Archana PR; Mohan SG; Anto RJ; Sadasivan C
    J Cell Biochem; 2019 Oct; 120(10):16643-16657. PubMed ID: 31095793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.
    Fako VE; Wu X; Pflug B; Liu JY; Zhang JT
    J Med Chem; 2015 Jan; 58(2):778-84. PubMed ID: 25513712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and optimization of novel piperazines as potent inhibitors of fatty acid synthase (FASN).
    Martin MW; Lancia DR; Li H; Schiller SER; Toms AV; Wang Z; Bair KW; Castro J; Fessler S; Gotur D; Hubbs SE; Kauffman GS; Kershaw M; Luke GP; McKinnon C; Yao L; Lu W; Millan DS
    Bioorg Med Chem Lett; 2019 Apr; 29(8):1001-1006. PubMed ID: 30803804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and anticancer activity of some novel 1H-benzo[d]imidazole-5-carboxamide derivatives as fatty acid synthase inhibitors.
    Singh S; Paul S; Brás NF; Kundu CN; Karthikeyan C; Moorthy NSHN
    Bioorg Chem; 2023 Sep; 138():106658. PubMed ID: 37331170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.